#1
#1 out of 1
business18h ago
BB Biotech Q1 2026: Share price outperformance, narrowing discount and active portfolio repositioning
- BB Biotech achieved a 4.1% CHF total return in Q1 2026, outperforming the Nasdaq Biotechnology Index in CHF terms.
- The quarter showed a CHF 21 million net loss, driven by portfolio repositioning and market timing effects.
- BB Biotech narrowed its discount to NAV to 6.9% as of March 31, 2026.
- The portfolio expanded from 24 to 30 holdings with eleven new investments in oncology, rare diseases, immunology and cardiometabolic medicine.
- Major additions included Regeneron, Gilead, and Amgen to strengthen large-cap exposure.
- Terns Pharmaceuticals was acquired by Merck before quarter-end, positively impacting results.
- BB Biotech joined the SPI Select Dividend 20 Index in March 2026, reinforcing its dividend strategy.
- The 2026 investment guideline was updated to broaden the portfolio range to 20–50 positions.
- Net asset value declined modestly despite positive currency effects favoring USD and EUR terms.
- A senior US analyst was added to broaden coverage of large-cap biopharma within the portfolio.
- BB Biotech’s investment approach emphasizes clinically differentiated companies with advancing commercial profiles.
Vote 0